$3.88
▲ +0.5% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says
Overview
52-week range
$2.53
$5.45
46% of range
Avg surprise (last 3)
-0.3%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
373%
EM ±58.3% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $1.08 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.42 | $-0.41 | -2.4% | +25.0% | -4.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.45 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.59 | $-0.57 | -3.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.56 | $-0.59 | +5.1% | — | +5.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.71 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.74 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.66 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.75 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.82 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.73 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $0 | $0 | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-47M | $-49M | — | $-52M | $-71M | $-64M | — | $-69M |
| Net income | $123M | $-48M | — | $-50M | $-69M | $-61M | — | $-67M |
| EPS (diluted) | $1.08 | $-0.42 | — | $-0.45 | $-0.62 | $-0.56 | — | $-0.71 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $225M | $50M | $78M | $76M | $33M | $50M | $164M | $66M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $290M | $150M | $193M | $228M | $277M | $324M | $378M | $242M |
| Total assets | $423M | $285M | $330M | $368M | $421M | $471M | $528M | $394M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $54M | $47M | $53M | $54M | $67M | $59M | $64M | $64M |
| Total equity | $369M | $238M | $277M | $314M | $354M | $412M | $463M | $330M |